Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio
Milan, Italy (ITALY01, 40) Amsterdam, Netherlands Madrid, Spain Lisbon, Portugal London, United Kingdom Brussels, Brussels-Capital Region, Belgium Barcelona, Spain Frankfurt, Hesse, Germany Warsaw, Poland Paris, France Full time R DTAS Strategic Advisory Consulting (Health Economics /